A successful cord blood transplant in a child with second accelerated phase chronic myeloid leukemia following lymphoid blast crisis

Bone Marrow Transplant. 2000 Jan;25(2):213-5. doi: 10.1038/sj.bmt.1702105.

Abstract

We describe a 5-year-old girl with Ph(+) CML who received a cord blood transplant in a second accelerated phase after a very early lymphoid blast crisis. She was induced into CR by ALL-directed chemotherapy and then maintained with IFN-alpha2b together with weekly rotational chemotherapy. Nineteen months after diagnosis, her mother gave birth to an HLA-compatible sibling, whose cord blood was cryopreserved. The patient's second acceleration occurred 22 months after the CML diagnosis. The subsequent conditioning regimen included busulfan 16 mg/kg, Ara-C 12 g/m2 and melphalan 140 mg/m2. In order to prevent GVHD, CsA alone was administered, 3 mg/kg i.v. per day for a total of 40 days. The total number of nucleated cells infused was 0.8 x 108/kg, with CD34+ cells 1.8 x 106/kg and CFU-GM 1 x 104/kg. Engraftment occurred on day +35. Respiratory distress, severe VOD and grade II acute gastrointestinal GVHD complicated the post-transplant period. No chronic GVHD occurred. The girl is alive 23 months after transplantation with complete donor chimerism; both Ph chromosome and bcr/abl RNA are negative. Bone Marrow Transplantation (2000) 25, 213-215.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blast Crisis / complications
  • Blast Crisis / drug therapy
  • Blast Crisis / pathology*
  • Blast Crisis / therapy
  • Blood Component Transfusion / adverse effects
  • Child, Preschool
  • Female
  • Fetal Blood* / cytology
  • Fetal Blood* / immunology
  • Graft Survival
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / immunology
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility Testing
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukemia, Myeloid, Accelerated Phase / complications
  • Leukemia, Myeloid, Accelerated Phase / genetics
  • Leukemia, Myeloid, Accelerated Phase / pathology*
  • Leukemia, Myeloid, Accelerated Phase / therapy*
  • Male
  • Transplantation Conditioning / adverse effects
  • Treatment Outcome